|
1
|
Lu J, Wang W, Xu M, Li Y, Chen C and Wang
X: A global view of regulatory networks in lung cancer: An approach
to understand homogeneity and heterogeneity. Semin Cancer Biol.
42:31–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu J, Zhang B, Wu M, Li H, Niu R, Ying G
and Zhang N: Screening of a PKC zeta-specific kinase inhibitor
PKCzI257.3 which inhibits EGF-induced breast cancer cell
chemotaxis. Invest New Drugs. 28:268–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Butler AM, Scotti BML, Li S, Smith KE,
Fields AP and Murray NR: Protein kinase C zeta regulates human
pancreatic cancer cell transformed growth and invasion through a
STAT3-dependent mechanism. PLoS One. 8:e720612013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Queisser MA, Dada LA, Deiss-Yehiely N,
Angulo M, Zhou G, Kouri FM, Knab LM, Liu J, Stegh AH, DeCamp MM, et
al: HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung
tumor growth. Am J Respir Crit Care Med. 190:688–698. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
LaVallie ER, Chockalingam PS,
Collins-Racie LA, Freeman BA, Keohan CC, Leitges M, Dorner AJ,
Morris EA, Majumdar MK and Arai M: Protein kinase Czeta is
up-regulated in osteoarthritic cartilage and is required for
activation of NF-kappaB by tumor necrosis factor and interleukin-1
in articular chondrocytes. J Biol Chem. 281:24124–24137. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Abdel-Halim M, Darwish SS, ElHady AK,
Hoppstädter J, Abadi AH, Hartmann RW, Kiemer AK and Engel M:
Pharmacological inhibition of protein kinase C (PKC)ζ downregulates
the expression of cytokines involved in the pathogenesis of chronic
obstructive pulmonary disease (COPD). Eur J Pharm Sci. 93:405–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diaz-Meco MT and Moscat J: The atypical
PKCs in inflammation: NF-κB and beyond. Immunol Rev. 246:154–167.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morin C, Fortin S and Rousseau E:
Bronchial inflammation induced PKCζ over-expression: Involvement in
mechanical properties of airway smooth muscle. Can J Physiol
Pharmacol. 90:261–269. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu M, Wang HF and Zhang HZ: Expression of
RECK and MMPs in hepatoblastoma and neuroblastoma and comparative
analysis on the tumor metastasis. Asian Pac J Cancer Prev.
16:4007–4011. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merdad A, Karim S, Schulten HJ, Dallol A,
Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM and
Al-Qahtani MH: Expression of matrix metalloproteinases (MMPs) in
primary human breast cancer: MMP-9 as a potential biomarker for
cancer invasion and metastasis. Anticancer Res. 34:1355–1366.
2014.PubMed/NCBI
|
|
11
|
Parks WC, Wilson CL and López-Boado YS:
Matrix metalloproteinases as modulators of inflammation and innate
immunity. Nat Rev Immunol. 4:617–629. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Babykutty S, Suboj P, Srinivas P, Nair AS,
Chandramohan K and Gopala S: Insidious role of nitric oxide in
migration/invasion of colon cancer cells by upregulating MMP-2/9
via activation of cGMP-PKG-ERK signaling pathways. Clin Exp
Metastasis. 29:471–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim HIe, Lee HS, Kim TH, Lee JS, Lee ST
and Lee SJ: Growth-stimulatory activity of TIMP-2 is mediated
through c-Src activation followed by activation of FAK
PI3-kinase/AKT, and ERK1/2 independent of MMP inhibition in lung
adenocarcinoma cells. Oncotarget. 6:42905–42922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamura T, Nakanishi K, Hiroi S, Kumaki
F, Sato H, Aida S and Kawai T: Expression of membrane-type-1-matrix
metalloproteinase and metalloproteinase-2 in nonsmall cell lung
carcinomas. Lung Cancer. 35:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang F, Dong W, Zeng W, Zhang L, Zhang C,
Qiu Y, Wang L, Yin X, Zhang C and Liang W: Naringenin prevents
TGF-β1 secretion from breast cancer and suppresses pulmonary
metastasis by inhibiting PKC activation. Breast Cancer Res.
18:382016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paul A, Danley M, Saha B, Tawfik O and
Paul S: PKCζ Promotes Breast Cancer Invasion by Regulating
Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via
NFκB-p65. Sci Rep. 5:125202015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
S LH Yang, Li W YL, Ni M ZL and Yin CaZB:
Expression and correlation of PKCζ, MMP-2 and MMP-9 in breast
cancer. Chin J Clin Exp Pathol. 30:958–962. 2014.
|
|
19
|
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A
and van Beek E Jr: The 7th lung cancer TNM classification and
staging system: Review of the changes and implications. World J
Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rajagopalan S, Moyle MW, Joosten I and
Long EO: DNA-PKcs controls an endosomal signaling pathway for a
proinflammatory response by natural killer cells. Sci Signal.
3:ra142010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim PS, Sutton CR and Rao S: Protein
kinase C in the immune system: From signalling to chromatin
regulation. Immunology. 146:508–522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fields AP and Regala RP: Protein kinase C
iota: Human oncogene, prognostic marker and therapeutic target.
Pharmacol Res. 55:487–497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Antal CE, Hudson AM, Kang E, Zanca C,
Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari
FB, et al: Cancer-associated protein kinase C mutations reveal
kinase's role as tumor suppressor. Cell. 160:489–502. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun R, Gao P, Chen L, Ma D, Wang J,
Oppenheim JJ and Zhang N: Protein kinase C zeta is required for
epidermal growth factor-induced chemotaxis of human breast cancer
cells. Cancer Res. 65:1433–1441. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma NZF, Guo HZX, Cao SNR and Zhang N:
Correlation between PKCζ expression and invasion, metastasis and
prognosis of adenoearcinoma of the lung. Chin J Clin Oncol.
37:557–560. 2010.
|
|
26
|
Kuo HY, Huang YS, Tseng CH, Chen YC, Chang
YW, Shih HM and Wu CW: PML represses lung cancer metastasis by
suppressing the nuclear EGFR-mediated transcriptional activation of
MMP2. Cell Cycle. 13:3132–3142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu Y, Ding Z, Jian H, Shen L, Zhu L and Lu
S: Prognostic value of MMP9 activity level in resected stage I B
lung adenocarcinoma. Cancer Med. 5:2323–2331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
King PT: Inflammation in chronic
obstructive pulmonary disease and its role in cardiovascular
disease and lung cancer. Clin Transl Med. 4:682015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
González-Arriaga P, Pascual T,
García-Alvarez A, Fernández-Somoano A, López-Cima MF and Tardón A:
Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer
risk and survival. BMC Cancer. 12:1212012. View Article : Google Scholar : PubMed/NCBI
|
